We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology
Product News

Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology

Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology
Product News

Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bruker has announced a collaboration between Bruker and Nextval for high-throughput screening of drugs and their metabolites using Bruker's ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval's MassInsight technology.

The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam II™ laser with its Perpetual Ion Source for unrivalled productivity, ensuring optimum performance for low concentration high-throughput screening.

The versatility of Bruker's Compass™ software allows integration with Nextval's screening technology to maximize sample density and reduce sample analysis costs.

Nextval's MassInsight screening technology is based on novel surface chemistries coupled with unique microarray acoustic deposition methods (EDC Biosystems & BioSero LLC) that address critical needs in several industries including the pharmaceutical, testing and industrial markets.

Dr. Matthew Greving, CSO of Nextval, stated: "The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity."

Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialize their MassInsight technology for high-throughput enzyme assays.

Dr. Paul Speir, Senior Vice President of Bruker Daltonics stated: "We are excited by the combination of Nextval's MassInsight technology with the information rich, high throughput capabilities provided by the ultrafleXtreme. Moreover, we are pleased to support Nextval in their efforts to develop this important technology for the rapid and economical screening of drug candidates."

Advertisement